SOURCE-LINKED STUDY SUMMARY
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
What was studied?
This double-blind, randomized phase 3a trial compared CagriSema with placebo. Primary outcomes were weight change and the proportion losing at least 5%; glucose measures and safety were additional outcomes.
What changed?
Mean weight fell 13.7% versus 3.4%. More CagriSema recipients lost at least 5%. Glycated hemoglobin reached 6.5% or less in 73.5% versus 15.9%. Gastrointestinal events occurred in 72.5% versus 34.4%, mostly transient and mild or moderate.
Who was studied?
1206 adults with type 2 diabetes were randomized, 904 to CagriSema and 302 to placebo. Eligibility included BMI of at least 27 and glycated hemoglobin of 7–10%.
Studied exposure
Cagrilintide and semaglutide, 2.4 mg each once weekly, were compared with placebo for 68 weeks. Both groups received lifestyle intervention; the abstract does not specify route or starting doses.
What remains uncertain?
Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2502082